Cipla bags USFDA nod for Lanreotide Injection
Mumbai: Cipla Limited along with its subsidiary Cipla USA, Inc., announced that it has received final approval for its Lanreotide Injection, from the United States Food and Drug Administration (USFDA).
The FDA approval was based on a New Drug Application (NDA) submitted under the 505(b)(2) filing pathway. Lanreotide Injection is supplied in 60 mg/0.2 mL, 90 mg/0.3 mL, and 120 mg/0.5 mL singledose pre-filled syringes.
It is indicated for the treatment of patients with Acromegaly and Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs).
Umang Vohra (MD and Global CEO, Cipla Limited) said, "We are pleased to receive the final approval for Lanreotide injection from the USFDA. Enabling access to high-quality treatments is core to our purpose of "Caring for Life".
Read also: Cipla to give nebulisers to primary health care centres in India
"This approval is a significant step for our US business and is in line with our aspiration to continue growth in our complex product pipeline and address unmet patient needs," the company said in a release.
The active ingredient, route of administration and strengths are the same as SOMATULINE DEPOT, from Ipsen Biopharmaceuticals Inc.
According to IQVIA, SOMATULINE DEPOT had US sales of approximately $867M for the 12-month period ending October 2021.
Read also: Cipla to acquire 33 percent stake in Clean Max Auriga Power
Cipla Limited is an Indian multinational pharmaceutical and biotechnology company, headquartered in Mumbai, India. The Company was founded by Khwaja Abdul Hamied in 1935 in Mumbai.
Cipla primarily develops medicines to treat respiratory, cardiovascular disease, arthritis, diabetes, weight control, depression, and other medical conditions.
Read also: CDSCO panel asks Cipla to include more Govt sites in Budesonide, Formoterol FDC study
